The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.
